keynote-055:pembrolizumab in hnscc
Published 7 years ago • 92 plays • Length 5:00Download video MP4
Download video MP3
Similar videos
-
4:46
preliminary results from keynote-055: pembrolizumab in hnscc
-
1:41
dr. bauml on keynote-055 study for patients with hnscc
-
5:03
making strides in head and neck cancer: keynote-055 ...
-
11:47
pembrolizumab in hnscc
-
5:34
pembrolizumab for recurrent hnscc
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
4:17
asco 2016 – treating head/ neck cancer – keynote 55: pembrolizumab for heavily pre-treated pts
-
1:48
post hoc keynote-040 analysis: pembrolizumab for hnscc produces lasting immune effect
-
7:03
pembrolizumab for frontline head and neck cancer: keynote-048 results
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
2:17
#esmo22 highlights on pembrolizumab with crt in locally advanced hnscc: the keynote-412 study
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
4:42
pembrolizumab for recurrent head and neck squamous cell carcinomas (hnscc)
-
1:58
dr. rischin on keynote-048 results in head and neck squamous cell carcinoma
-
1:00
dr. ferris on pembrolizumab and nivolumab in head and neck cancer
-
1:39
pembrolizumab and epacadostat for nsclc: echo-306/keynote-715
-
1:06
dr. cohen discusses the keynote-040 trial in head and neck cancer